Kyung Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kyung Kim has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
Ho Yeong Lim
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2 shared publicationsJeeyun Lee
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
2 shared publicationsAdam J. Bass
Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
1 shared publicationAmirAli Talasaz
Department of Medical Affairs, Guardant Health, Redwood City, CA, USA
1 shared publication- Andrey Loboda
Merck & Co., Inc. 7 Boston, MA
1 shared publication Byong Chang Jeong
Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Korean Medical Science
- Vol. 40 (16) , e54
Clinical Exome-Based Redefinition and Reclassification of Retinitis Pigmentosa
Park HS, et al. J Korean Med Sci. 2024 Dec;40(16):e54. https://doi.org/10.3346/jkms.2025.40.e54
- 1 January 2025
- Published by XMLink in Journal of Korean Medical Science
- Vol. 40 (16) , e54
Open AccessClinical Exome-Based Redefinition and Reclassification of Retinitis Pigmentosa
Park HS, et al. J Korean Med Sci. 2024 Dec;40(16):e54. https://doi.org/10.3346/jkms.2025.40.e54
- Open Access
- 1 December 2020
- Published by Society for Neuroscience in The Journal of Neuroscience
- Vol. 41 (3) , 446-460
Role ofMycProto-Oncogene as a Transcriptional Hub to Regulate the Expression of Regeneration-Associated Genes following Preconditioning Peripheral Nerve Injury
Preconditioning peripheral nerve injury enhances the intrinsic growth capacity of DRGs sensory axons by inducing transcriptional upregulation of the regeneration-associated genes (RAGs). However, it is still unclear how preconditioning injury leads to the orchestrated induction of many RAGs. The present study identifiedMycproto-oncogene as a transcriptional hub gene to regulate the expression of a distinct subset of RAGs in DRGs following the preconditioning injury. We demonstrated that c-MYC bound to the promoters of certain RAGs, such asJun,Atf3, andSprr1a, and thatMycupregulation following SNI preceded that of the RAGs bound by c-MYC. Marked DNA methylation of theMycexon 3 sequences was implicated in the early transcriptional activation and accompanied by open histone marks.Mycdeletion led to a decrease in the injury-induced expression of a distinct subset of RAGs, which were highly overlapped with the list of RAGs that were upregulated byMycoverexpression. Following dorsal hemisection spinal cord injury in female rats,Mycoverexpression in DRGs significantly prevented the retraction of the sensory axons in a manner dependent on its downstream RAG,June. Our results suggest thatMycplays a critical role in axon regeneration via its transcriptional activity to regulate the expression of a spectrum of downstream RAGs and subsequent effector molecules. Identification of more upstream hub transcription factors and the epigenetic mechanisms specific for individual hub transcription factors would advance our understanding of how the preconditioning injury induces orchestrated upregulation of RAGs.
- 1 December 2020
- Published by Society for Neuroscience in The Journal of Neuroscience
- Vol. 41 (3) , 446-460
Open AccessRole ofMycProto-Oncogene as a Transcriptional Hub to Regulate the Expression of Regeneration-Associated Genes following Preconditioning Peripheral Nerve Injury
Preconditioning peripheral nerve injury enhances the intrinsic growth capacity of DRGs sensory axons by inducing transcriptional upregulation of the regeneration-associated genes (RAGs). However, it is still unclear how preconditioning injury leads to the orchestrated induction of many RAGs. The present study identifiedMycproto-oncogene as a transcriptional hub gene to regulate the expression of a distinct subset of RAGs in DRGs following the preconditioning injury. We demonstrated that c-MYC bound to the promoters of certain RAGs, such asJun,Atf3, andSprr1a, and thatMycupregulation following SNI preceded that of the RAGs bound by c-MYC. Marked DNA methylation of theMycexon 3 sequences was implicated in the early transcriptional activation and accompanied by open histone marks.Mycdeletion led to a decrease in the injury-induced expression of a distinct subset of RAGs, which were highly overlapped with the list of RAGs that were upregulated byMycoverexpression. Following dorsal hemisection spinal cord injury in female rats,Mycoverexpression in DRGs significantly prevented the retraction of the sensory axons in a manner dependent on its downstream RAG,June. Our results suggest thatMycplays a critical role in axon regeneration via its transcriptional activity to regulate the expression of a spectrum of downstream RAGs and subsequent effector molecules. Identification of more upstream hub transcription factors and the epigenetic mechanisms specific for individual hub transcription factors would advance our understanding of how the preconditioning injury induces orchestrated upregulation of RAGs.
- 1 February 2019
- Published by Elsevier in Cancer Genetics
- Vol. 231-232, 54-61
Genomic landscape of synchronous tubulovillous adenoma and multiple non-familial colon cancers from a single patient
- 1 February 2019
- Published by Elsevier in Cancer Genetics
- Vol. 231-232, 54-61
Genomic landscape of synchronous tubulovillous adenoma and multiple non-familial colon cancers from a single patient
- Top Cited Papers
- 16 July 2018
- Published by Springer Nature in Nature Medicine
- Vol. 24 (9) , 1449-1458
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
Clinical studies support the efficacy of programmed cell death 1 (PD-1) targeted therapy in a subset of patients with metastatic gastric cancer (mGC). With the goal of identifying determinants of response, we performed molecular characterization of tissues and circulating tumor DNA (ctDNA) from 61 patients with mGC who were treated with pembrolizumab as salvage treatment in a prospective phase 2 clinical trial. In patients with microsatellite instability-high and Epstein–Barr virus-positive tumors, which are mutually exclusive, dramatic responses to pembrolizumab were observed (overall response rate (ORR) 85.7% in microsatellite instability-high mGC and ORR 100% in Epstein–Barr virus-positive mGC). For the 55 patients for whom programmed death-ligand 1 (PD-L1) combined positive score positivity was available (combined positive score cut-off value ≥1%), ORR was significantly higher in PD-L1(+) gastric cancer when compared to PD-L1(−) tumors (50.0% versus 0.0%, P value <0.001). Changes in ctDNA levels at six weeks post-treatment predicted response and progression-free survival, and decreased ctDNA was associated with improved outcomes. Our findings provide insight into the molecular features associated with response to pembrolizumab in patients with mGC and provide biomarkers potentially relevant for the selection of patients who may derive greater benefit from PD-1 inhibition.
- 16 July 2018
- Published by Springer Nature in Nature Medicine
- Vol. 24 (9) , 1449-1458
Top Cited PapersComprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
Clinical studies support the efficacy of programmed cell death 1 (PD-1) targeted therapy in a subset of patients with metastatic gastric cancer (mGC). With the goal of identifying determinants of response, we performed molecular characterization of tissues and circulating tumor DNA (ctDNA) from 61 patients with mGC who were treated with pembrolizumab as salvage treatment in a prospective phase 2 clinical trial. In patients with microsatellite instability-high and Epstein–Barr virus-positive tumors, which are mutually exclusive, dramatic responses to pembrolizumab were observed (overall response rate (ORR) 85.7% in microsatellite instability-high mGC and ORR 100% in Epstein–Barr virus-positive mGC). For the 55 patients for whom programmed death-ligand 1 (PD-L1) combined positive score positivity was available (combined positive score cut-off value ≥1%), ORR was significantly higher in PD-L1(+) gastric cancer when compared to PD-L1(−) tumors (50.0% versus 0.0%, P value <0.001). Changes in ctDNA levels at six weeks post-treatment predicted response and progression-free survival, and decreased ctDNA was associated with improved outcomes. Our findings provide insight into the molecular features associated with response to pembrolizumab in patients with mGC and provide biomarkers potentially relevant for the selection of patients who may derive greater benefit from PD-1 inhibition.
- Open Access
- 1 February 2018
- Published by Elsevier in Translational Oncology
- Vol. 11 (1) , 37-42
Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract
- 1 February 2018
- Published by Elsevier in Translational Oncology
- Vol. 11 (1) , 37-42
Open AccessMolecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract